BPH Mann 78 Jahre

Young man and his experience with BPH and UroLift.

Wo die männlichen Prostata bei Männern Video

Die Erfindung betrifft pharmazeutische Kombinationen zum Ausgleich eines absoluten und relativen Testosteron-Defizits beim Mann mit gleichzeitiger Prophylaxe für die Entstehung einer beningnen Prosta tahyperplasie BPH bzw.

Verschiedene endokrine Funktionen verändern sich im Verlauf des Alte rungsprozesses. Various endocrine functions vary during the Old insurance process. The normal aging process in men is associated with a Abnah me of testicular function, especially with a decrease in serum testosterone levels. Serum Testeron secretion is characteristics for the secondary sex, responsible libido and potency and also has poiesis an influence on mood and intellectual skills to the erythro, kelmasse bone metabolism, protein anabolism and Mus, fat distribution and certain CNS functions.

In decreased serum testosterone levels, a decrease of libido and potency, as well as fatigue, decreased muscle mass, osteoporosis, hot flushes, sweating and mild anemia can occur clinically. Allerdings werden BPH Mann 78 Jahre für die Entstehung und Manifestation sowohl der benignen Prostatahyperplasie BPH als BPH Mann 78 Jahre des Prosta takarzinoms eine wesentliche Rolle zugeschrieben. However, androgens are used for the development and manifestation of both the benign prostatic hyperplasia BPH and the Prosta takarzinoms an essential role attributed.

Im höheren Lebensalter treten Erkrankungen der Prostata gehäuft auf. In old age diseases occur frequently prostate. Hypogonadal men or neuters never develop BPH. Geiler, J. In: Bhasin et BPH Mann 78 Jahre. Levine, AC Trends Endocrinol. Serio, M. In: Bhasin et al eds. Pharmacology, biology, and clinical applications BPH Mann 78 Jahre androgens John Wiley, New. Proven all indicated clinical symptoms testosterone levels occur both in men over 50 than in younger men with various chronic diseases and permanent stress already common in serum at the lower limit of normal Aus der Literatur bzw.

A testosterone replacement therapy without danger to the prostate is not shown. In the literature it is BPH Mann 78 Jahre that androgen improves the physical and mental well-being in old age [Bagatell et al. Jedoch wird BPH Mann 78 Jahre Androgensubstitution bei älteren Männern mit erniedrig ten Serum-Testosteron-Spiegeln der unterschiedlichsten Ursachen BPH Mann 78 Jahre genwärtig noch kontrovers BPH Mann 78 Jahre und immer das erhöhte Risiko von Erkrankungen der Prostata durch Überstimulierung in den Vordergrund gestellt.

However, the androgen is ge still controversial BPH Mann 78 Jahre older men with decrement th serum testosterone levels of various causes genwärtig and always found the increased risk of diseases of BPH Mann 78 Jahre prostate by overstimulation to the fore. Von einer Androgen-Replacement-Therapie des älteren oder frühzeitig gealterten Mannes in Analogie zur postmenopausalen Hormonsubstitu tion der Frau wird daher gewarnt [Rolf, C.

Nieschlag: Senes zenz In E. Nieschlag und HM Behre Hrsg. From BPH Mann 78 Jahre androgen replacement therapy for older or prematurely aged man analogously to postmenopausal women Hormonsubstitu tion is therefore warned [Rolf, C. Nieschlag and HM Behre ed. Springer ; Springer ; Jackson, JA et al. Jackson, BPH Mann 78 Jahre et al. Androgensubstitution des älteren Mannes. Jocken Hoevel, F. In: Allolio and Schulte eds : Practical endocrinology.

Auch Holmäng, S. Also Holmäng, S. Prostate 23, konnten z. Prostate 23, were for. In studies on male contraception with testosterone enanthate de WUR found in young men under exogenous testosterone administration by means of transrectal ultrasound increasing the Prosta ta [Wu, CW et al. Wallace, EM et al. The patent document DE 10 A1 describes the use of dehydroepiandrosterone in combination with Aromatsehemmern to Be treatment of a relative and absolute Andogenmangels in men hypoandrogenism.

Aromatase inhibitors within the meaning of this patent are all those compounds which inhibit the formation of estrogens from their metabolic precursors DHEA here by inhibition of the aromatase En zyms inhibition of the biosynthesis. Eine Androgentherapie mit gleichzeitigem Schutz der Prostata ist je doch nicht aufgezeigt.

Androgen therapy with simultaneous protection of the prostate is not ever identified. Auch hier ist eine Androgentherapie mit gleichzeitigem Schutz der Pro stata nicht ableitbar. Again, androgen therapy with while protecting the Pro not BPH Mann 78 Jahre derived.

Aufgabe der vorliegenden Erfindung ist es, geeignete Kombinati onspräparate zum Ausgleich eines absoluten und relativen Testosteron- Defizits beim Mann mit gleichzeitigem Schutz der Prostata zu definieren und dabei die oben genannten Nachteile und Wirkungen zu vermeiden.

Object of BPH Mann 78 Jahre present invention is suitable combination Nati onspräparate to compensate for an absolute and relative testosterone deficit in men while protecting the prostate to define and to avoid the aforementioned disadvantages and effects.

The object is binationspräparaten by the inventive use of Kom according to claim 1 for compensating for an absolute and relative testosterone deficit with simultaneous treatment of nignen be prostatic hyperplasia BPH was dissolved.

The inventive use of the combination preparations characterized prior preferably that the natural androgen piandrosteron one of the substances testosterone, testosterone undecanoate, Dehydroe, dehydroepiandrosterone sulphate, testosterone propionate, testosterone enanthate, testosterone buciclate, testosterone cypionate or androstenedione, and the synthetic androgen one of the substances methyltestosterone, fluoxymesterone BPH Mann 78 Jahre, danazol, mesterolone, Nandro londecanoat, nandrolone, oxandrolone, oxymetholone, stanozolol is.

It is advantageous that the dosage of the androgen, wherein the pitch of to mg of testosterone undecanoate in all is from 4 to 14 weeks. Besonders vorteilhaft ist dabei die Gabe von mg alle 9 bis 10 Wo chen an Testosteronundecanoat. The inventive use of the combination preparations characterized prior preferably that the progestin component is a steronacetat of the substances dienogest, levonorgestrel, gestodene, desogestrel, norgestimate, norethisterone, norethisterone acetate, levonorgestrel or progesterone, chlormadinone acetate, cyproterone acetate, Medroxyproge, megestrol acetate, dydrogesterone, trimegestone or no BPH Mann 78 Jahre is.

It is BPH Mann 78 Jahre that the dosage of progestogen is from Die Antiestrogen-Komponente ist vorzugsweise Tamoxifene, Raloxifen. The antiestrogen component is preferably Tamoxifene, raloxifene. Panomifen, Toremifen, Iproxifene oder Idoxifen. Panomifene, toremifene, Iproxifene or idoxifene. The GnRH analogues component is preferably buserelin, goserelin, nafarelin, triptorelin or deslorelin, leuprolide and leuprolide acetate. The phosphodiesterase inhibitor component is preferably amrinone, milrinone, Trapidil, papaverine, vesnarinone or sildenafil.

Applikationsformen BPH Mann 78 Jahre. Die pharmazeutischen Zubereitungsformen können die Kombinationen als einheitliche Form darstellen oder auch zwei getrennte Formulierun gen beinhalten. The pharmaceutical formulations may also represent combinations as a single form or two separate Formulierun include gene. Dabei können es sich um Peroralia, z. It can be administered orally to such.

Tabletten, Kapseln und Dragees, um perkutane Zubereitungsformen, z. As tablets, capsules and coated tablets, percutaneous formulations such. The formulations are produced in a conventional manner under Ver application customary auxiliaries and excipients, as described for example in "Remington's Pharmaceutical Sciences Handbook, Hack Pub. Es wurde eine pharmazeutische Kombinationen zum Ausgleich eines absoluten und relativen Testosteron-Defizits beim Mann mit gleichzeiti ger Prophylaxe der benignen Prostatahyperplasie BPH gefunden.

It has been found a pharmaceutical combinations for compensating BPH Mann 78 Jahre an absolute and relative testosterone deficit in men with benign prostatic hyperplasia gleichzeiti ger prophylaxis of BPH. Compared to the inventive combination of each drug can not reach to that level, only signifi cant side effects alone the desired goal.

After 24 hours, dissolved in ethanol steroids in fresh test medium final concentration of 0. Aus der Abb. From Fig. Depending on the dose of the second component - here the progestin DNG - however, the androgen-dependent Zellprolife ration is inhibited prostate carcinoma cell line. The dienogest effect is primarily peripherally on the genitalia Oettel, M. Furthermore, the inhibition of an induced by androgens prostate growth, which has been treated with a combination according to the invention was studied in animal experiments.

Two weeks after castration was the control animals Testo steronpropionat TP alone - administered 0. Am Versuchsende wurden die Prostatagewichte der Mäuse ermittelt und die Versuchsgruppen verglichen. At the end of the test, the prostate weights of the mice were determined and the experimental groups compared. In Tabelle 1 sind die ermittelten Prostatagewichte der behandelten Mäuse während des Versuchsverlaufes aufgezeigt.

In Table 1, the detected prostate weights of the treated mice during the experimental course are shown. From Table 1 it can be seen that the selected pure testosterone dose - 0. Damit ist nachweislich der Ausgleich des relativen Testosteron-Defizits und der gleichzeitige Schutz der Prostata gewährleistet.

Thus balancing the relative testosterone deficit and simultaneously protect the prostate is demonstrably guaranteed. The inventive combinations drugs are provided that compensate for a relative testosterone deficiency in men and simultaneously protect the prostate. The invention relates to pharmaceutical combinations for compensating for an absolute and relative testosterone deficiency in men while simultaneously preventing the development of benign prostatic hypertrophy BPH or of prostatic cancer.

The inventive combinations contain a natural or synthetic androgen combined with a gestagen, an antigestagen, an antiestrogen, a GnRH analog, a testosterone-5 alpha -reductase inhibitor, an alpha -adrenergic blocking BPH Mann 78 Jahre or a phosphodiesterase inhibitor. Compared to the inventive combinations, each active ingredient cannot carry out the desired objective alone.

Verwendung von Kombinationspräparaten, enthaltend 1. The use of combination preparations containing 1. The use of combination preparations according to claim 1, characterized in that the natural Androgenkomponente testosterone, testosterone testosterone undecanoate, dehydroepiandrosterone, dehydroepiandrosterone sulphate, testosterone propionate, testosterone enanthate, testosterone buciclate, testosterone cypionate or androstenedione is.

The use BPH Mann 78 Jahre combination preparations according to claim 1, characterized in that the synthetic Androgenkomponente methyl testosterone, fluoxymesterone, danazol, mesterolone, nandrolone decanoate, nandrolone phenylpropionate, oxandrolone, BPH Mann 78 Jahre, stanozolol is.

The use of combination preparations according to claim 1, characterized in that the progestin component is dienogest, levonorgestrel, gestodene, desogestrel, norgestimate, norethisterone, norethisterone acetate, levonorgestrel or progesterone, BPH Mann 78 Jahre acetate, cyproterone acetate, medroxyprogesterone acetate, megestrol acetate, dydrogesterone, trimegestone or nomegestrol is.

The use of combination preparations according to claim 1, characterized in that the antiestrogen component is Tamoxifene, raloxifene, panomifene, toremifene, idoxifene or Iproxifene.

Leuprolidacetat ist. The use of combination preparations according to claim 1, characterized in that the GnRH analogues component buserelin, goserelin, nafarelin, triptorelin or deslorelin, BPH Mann 78 Jahre and leuprolide acetate. The use of combination preparations according to claim 1, characterized in that the phosphodiesterase inhibitor component amrinone, milrinone, Trapidil, papaverine, vesnarinone or sildenafil. Use of a combination preparation according to at least one of claims 1 to 4, characterized in that it is in the form of tablets, capsules, coated tablets, transdermal therapy systems, ampoules, suppositories, gels, ointments, nasal drops, implants, compacts or biodegradable microspheres is used.

Pharmaceutical combinations to offset a testosterone deficit in men with prostate while protecting the.